keyword
MENU ▼
Read by QxMD icon Read
search

Zoster

keyword
https://www.readbyqxmd.com/read/29056075/an-updated-review-of-the-jak1-2-inhibitor-ruxolitininb-in-the-philadelphia-negative-myeloproliferative-neoplasms
#1
Natalia Curto-Garcia, Claire N Harrison
Ruxolitinib (Rux), a JAK1/2 inhibitor, has been approved for patients with myelofibrosis and in polycythemia vera with inadequate response/intolerance to hydroxycarbamide. Studies have demonstrated that Rux improves disease-related symptoms and splenomegaly. A late emerging observation from two Phase III trials was that Rux was associated with survival advantage in comparison with placebo or other available therapies in myelofibrosis. Important data suggest that for polycythemia vera Rux improved control of blood counts...
October 23, 2017: Future Oncology
https://www.readbyqxmd.com/read/29054900/herpes-zoster-ophthalmicus-in-a-1-year-old-child
#2
Zaid Makzal, Martin Edwards
No abstract text is available yet for this article.
October 20, 2017: BMJ Case Reports
https://www.readbyqxmd.com/read/29053937/studies-with-herpes-zoster-vaccines-in-immune-compromised-patients
#3
Myron J Levin, Eddy Bresnitz, Zoran Popmihajlov, Adriana Weinberg, Kai-Li Liaw, English Willis, Jeffrey R Curtis
INTRODUCTION: The active component of the herpes zoster vaccine (ZVL), recommended for people ≥50 years of age, is a live attenuated varicella-zoster virus. ZVL is contraindicated for immune compromised individuals, with limited regard to the degree of immunosuppression. Areas covered: This review evaluates phase I and II, and observational studies for ZVL and published reports of the off-label use of ZVL, for conditions and therapies for which investigators considered the risk-benefit for using ZVL to be favorable...
October 20, 2017: Expert Review of Vaccines
https://www.readbyqxmd.com/read/29053820/mood-disorders-and-risk-of-herpes-zoster-in-two-population-based-case-control-studies-in-denmark-and-the-united-kingdom
#4
Sigrun A J Schmidt, Sinéad M Langan, Henrik S Pedersen, Henrik C Schønheyder, Sara L Thomas, Liam Smeeth, Kathryn E Mansfield, Henrik T Sørensen, Harriet J Forbes, Mogens Vestergaard
We examined the association between mood disorders and risk of herpes zoster in two case-control studies using data from nationwide Danish registries and practices in the UK Clinical Practice Research Datalink. We included incident zoster cases diagnosed in general practice (using systemic antivirals as proxy in Denmark) or hospital during 1997-2013 in Denmark (n = 190,671) and during 2000-2013 in the UK (n = 177,361). We risk-set sampled four matched population controls per case. Conditional logistic regression analyses adjusted for zoster risk factors showed that the odds ratios (ORs) for previous mood disorder among cases vs...
October 19, 2017: American Journal of Epidemiology
https://www.readbyqxmd.com/read/29051967/clinical-efficacy-of-transforaminal-epidural-injection-for-management-of-zoster-associated-pain-a-retrospective-analysis
#5
Eung Don Kim, Ha Hyeon Bak, Dae Hyun Jo, Hue Jung Park
OBJECTIVES: Transforaminal epidural injection (TFEI) has superior accessibility to the dorsal root ganglion, which is an essential location of pain signaling in herpes zoster. However, the effectiveness of TFEI for herpes zoster patients has not previously been studied. We retrospectively analyzed the efficacy of TFEI for pain control and prevention of PHN in patients with acute and subacute herpes zoster. METHODS: Medical records of 137 patients who underwent TFEI for zoster-associated pain (ZAP) were reviewed...
October 19, 2017: Skeletal Radiology
https://www.readbyqxmd.com/read/29050801/projections-of-zoster-incidence-in-australia-based-on-demographic-and-transmission-models-of-varicella-zoster-virus-infection
#6
Valentina Costantino, Heather F Gidding, James G Wood
Re-exposure to varicella infection is believed to delay the occurrence of herpes zoster (HZ), which has led to predictions of increased HZ following introduction of varicella vaccination programs. However, there is evidence of rising HZ rates before vaccination was introduced. Here, we explore a potential explanation for this effect through demographic change leading to reductions in varicella exposure and boosting in the context of Australia over the 20th century. To study this hypothesis, we integrated observed changes in Australian birth and age-specific death rates with a varicella transmission model...
October 16, 2017: Vaccine
https://www.readbyqxmd.com/read/29047317/varicella-and-herpes-zoster-vaccine-development-lessons-learned
#7
Charlotte Warren-Gash, Harriet Forbes, Judith Breuer
Introduction Before vaccination, varicella zoster virus (VZV), which is endemic worldwide, led to almost universal infection. This neurotropic virus persists lifelong by establishing latency in sensory ganglia, where its reactivation is controlled by VZV-specific T-cell immunity. Lifetime risk of VZV reactivation (zoster) is around 30%. Vaccine development was galvanised by the economic and societal burden of VZV, including debilitating zoster complications that largely affect older individuals. Areas covered We describe the story of development, licensing and implementation of live attenuated vaccines against varicella and zoster...
October 19, 2017: Expert Review of Vaccines
https://www.readbyqxmd.com/read/29046461/human-embryonic-stem-cell-derived-neurons-are-highly-permissive-for-varicella-zoster-virus-lytic-infection
#8
Tomohiko Sadaoka, Cindi L Schwartz, Labchan Rajbhandari, Arun Venkatesan, Jeffrey I Cohen
Varicella-zoster virus (VZV) is highly cell-associated when grown in culture and has a much higher (4,000 to 20,000-fold increased) particle-to-plaque forming unit (PFU) ratio in vitro than herpes simplex virus (HSV). In contrast, VZV is highly infectious in vivo by airborne transmission. Neurons are major targets for VZV in vivo, in which the virus can establish latency and reactivate to produce infectious virus. Using neurons derived from human embryonic stem cells (hESC) and cell-free wild-type (WT) VZV, we demonstrate that neurons are nearly 100 times more permissive for WT VZV infection than very early passage human embryonic lung cells or MRC-5 diploid human fibroblasts, the cells used for vaccine production or virus isolation...
October 18, 2017: Journal of Virology
https://www.readbyqxmd.com/read/29045212/tofacitinib-or-adalimumab-versus-placebo-for-psoriatic-arthritis
#9
Philip Mease, Stephen Hall, Oliver FitzGerald, Désirée van der Heijde, Joseph F Merola, Francisco Avila-Zapata, Dorota Cieślak, Daniela Graham, Cunshan Wang, Sujatha Menon, Thijs Hendrikx, Keith S Kanik
BACKGROUND: Tofacitinib is an oral Janus kinase inhibitor that is under investigation for the treatment of psoriatic arthritis. We evaluated tofacitinib in patients with active psoriatic arthritis who previously had an inadequate response to conventional synthetic disease-modifying antirheumatic drugs (DMARDs). METHODS: In this 12-month, double-blind, active-controlled and placebo-controlled, phase 3 trial, we randomly assigned patients in a 2:2:2:1:1 ratio to receive one of the following regimens: tofacitinib at a 5-mg dose taken orally twice daily (107 patients), tofacitinib at a 10-mg dose taken orally twice daily (104), adalimumab at a 40-mg dose administered subcutaneously once every 2 weeks (106), placebo with a blinded switch to the 5-mg tofacitinib dose at 3 months (52), or placebo with a blinded switch to the 10-mg tofacitinib dose at 3 months (53)...
October 19, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/29045207/tofacitinib-for-psoriatic-arthritis-in-patients-with-an-inadequate-response-to-tnf-inhibitors
#10
Dafna Gladman, William Rigby, Valderilio F Azevedo, Frank Behrens, Ricardo Blanco, Andrzej Kaszuba, Elizabeth Kudlacz, Cunshan Wang, Sujatha Menon, Thijs Hendrikx, Keith S Kanik
BACKGROUND: Tofacitinib is an oral Janus kinase inhibitor that is under investigation for the treatment of psoriatic arthritis. We evaluated tofacitinib in patients with active psoriatic arthritis who had previously had an inadequate response to tumor necrosis factor (TNF) inhibitors. METHODS: In this 6-month randomized, placebo-controlled, double-blind, phase 3 trial, we randomly assigned 395 patients, in a 2:2:1:1 ratio, to four regimens: 5 mg of tofacitinib administered orally twice daily (132 patients); 10 mg of tofacitinib twice daily (132 patients); placebo, with a switch to 5 mg of tofacitinib twice daily at 3 months (66 patients); or placebo, with a switch to 10 mg of tofacitinib twice daily at 3 months (65 patients)...
October 19, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/29043719/varicella-zoster-virus-need-for-better-infection-prevention-and-control
#11
Per H Bjark, Egil Lingaas
No abstract text is available yet for this article.
October 16, 2017: Tidsskrift for Den Norske Lægeforening: Tidsskrift for Praktisk Medicin, Ny Række
https://www.readbyqxmd.com/read/29036443/the-association-of-perceived-mental-stress-sense-of-purpose-in-life-and-negative-life-events-with-the-risk-of-incident-herpes-zoster-and-postherpetic-neuralgia-the-shez-study
#12
Yukiko Takao, Yoshinobu Okuno, Yasuko Mori, Hideo Asada, Koichi Yamanishi, Hiroyasu Iso
This population-based prospective study examined the relationships of perceived mental stress, sense of purpose in life, and negative life events to the incidence of herpes zoster (HZ) and postherpetic neuralgia (PHN). The data were collected from 12,359 participants (aged ≥50 years old in Shozu County, Kagawa Prefecture, Japan) who answered a self-completed health questionnaire. During a 3-year follow-up between December 2008 and November 2012, HZ and PHN were diagnosed in 400 and 79 subjects, respectively...
September 20, 2017: American Journal of Epidemiology
https://www.readbyqxmd.com/read/29036392/update-from-the-advisory-committee-on-immunization-practices
#13
Sean T O'Leary, David W Kimberlin
The Advisory Committee on Immunization Practices (ACIP), a group of medical and public health experts, meets 3 times per year to develop recommendations for vaccine use in the United States. The group has 15 voting members, and each member's term is 4 years. ACIP members and Centers for Disease Control and Prevention (CDC) staff discuss the epidemiology of vaccine-preventable diseases and vaccine research, effectiveness, safety data, and clinical trial results. Representatives from the American Academy of Pediatrics (Carrie L...
September 25, 2017: Journal of the Pediatric Infectious Diseases Society
https://www.readbyqxmd.com/read/29032243/dna-methylation-patterns-are-related-to-co-morbidity-status-and-circulating-c-reactive-protein-levels-in-the-nursing-home-elderly
#14
Chris P Verschoor, Lisa M McEwen, Michael S Kobor, Mark B Loeb, Dawn M E Bowdish
Elderly residents of long-term care commonly exhibit a number of age-related health deficits, including impaired physical and cognitive function, chronic illnesses, and chronic inflammation. Given our previous data relating the phenotype and function of innate and adaptive leukocytes from the nursing home elderly to chronic conditions and inflammatory biomarkers, we hypothesized that these factors would influence the regulatory programming of immune cells, thereby contributing to immune dysfunction. Since DNA methylation represents both an important regulatory mechanism of cells as well as a biomarker of health and disease, we sought to characterize the methylome of peripheral blood mononuclear cells (PBMCs) from the nursing home elderly (n=23; 82-98years old, 70% female), and compare these patterns to pathological factors such as dementia, co-morbidity score and frailty, and immune-related factors such as serum C-reactive protein (CRP) and cytokine levels and varicella-zoster virus (VZV) vaccine responsiveness...
October 12, 2017: Experimental Gerontology
https://www.readbyqxmd.com/read/29029303/clinical-usage-of-the-candidate-adjuvanted-hz-su-zoster-vaccine-re-vaccination-of-recipients-of-live-attenuated-zoster-vaccine-and-co-administration-with-a-seasonal-influenza-vaccine
#15
Michael N Oxman, Ruth Harbecke, David M Koelle
No abstract text is available yet for this article.
September 26, 2017: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/29029224/immunogenicity-and-safety-of-an-adjuvanted-herpes-zoster-subunit-vaccine-co-administered-with-seasonal-influenza-vaccine-in-adults-aged-50-years-and-older
#16
Tino F Schwarz, Naresh Aggarwal, Beate Moeckesch, Isabelle Schenkenberger, Carine Claeys, Martine Douha, Olivier Godeaux, Katrijn Grupping, Thomas C Heineman, Marta Lopez Fauqued, Lidia Oostvogels, Peter Van den Steen, Himal Lal
Background: The immunogenicity and safety of an adjuvanted herpes zoster subunit vaccine (HZ/su) when co-administered with a quadrivalent seasonal inactivated influenza vaccine (IIV4) was investigated in a phase 3, open-label, randomized clinical trial in adults aged ≥50 years. Methods: Subjects were randomized 1:1 to receive either HZ/su (VZV glycoprotein E [gE]; AS01B Adjuvant System) and IIV4 at day 0 followed by a second HZ/su dose at month 2 (Co-ad group), or IIV4 at month 0 and HZ/su at months 2 and 4 (Control group)...
September 26, 2017: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/29029122/immunogenicity-and-safety-of-the-hz-su-adjuvanted-herpes-zoster-subunit-vaccine-in-adults-previously-vaccinated-with-a-live-attenuated-herpes-zoster-vaccine
#17
Katrijn Grupping, Laura Campora, Martine Douha, Thomas C Heineman, Nicola P Klein, Himal Lal, James Peterson, Ilse Vastiau, Lidia Oostvogels
Background: Protection against herpes zoster (HZ) induced by the live-attenuated zoster vaccine Zostavax (ZVL) wanes within 3-7 years. Re-vaccination may renew protection. We assessed whether (re)-vaccination with the adjuvanted HZ subunit vaccine candidate (HZ/su) induced comparable immune responses in previous ZVL-recipients and ZVL-naïve individuals (HZ-NonVac). Methods: In an open-label, multicenter study (NCT02581410), adults ≥65 years of age, vaccinated with ZVL ≥5 years previously (HZ-PreVac), were matched to HZ-NonVac adults...
September 26, 2017: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/29029120/diagnostic-usefulness-of-varicella-zoster-virus-real-time-pcr-with-dna-from-saliva-and-plasma-in-patients-with-herpes-zoster
#18
Seong Yeon Park, Ji Yeun Kim, Ji-Ae Kim, Jisoo Kwon, Sun-Mi Kim, Na Young Jeon, Min-Chul Kim, Yong Pil Chong, Sang Oh Lee, Sang-Ho Choi, Yang Soo Kim, Jun Hee Woo, Sung-Han Kim
Background: We evaluated the diagnostic usefulness of PCR for detecting varicella zoster virus (VZV) infection and reactivation of VZV using saliva and plasma VZV DNA from subjects suspected of having herpes zoster (HZ), and healthy volunteers exposed to stress, respectively. Methods: Study subjects were patients with HZ (n = 52), control patients with zoster-mimicking conditions (n = 30), and healthy university students (n = 27). VZV DNA was examined in saliva and plasma samples by real-time PCR...
September 26, 2017: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/29025327/post-herpetic-neuralgia-a-review-of-current-management-and-future-directions
#19
John Schutzer-Weissmann, Paul Farquhar-Smith
Post-herpetic neuralgia (PHN) is common and treatment is often suboptimal with less than half of patients achieving adequate 50% pain relief. As an area of unmet clinical need and as an archetype of neuropathic pain, it deserves the attention of clinicians and researchers. Areas covered: This review summarises the epidemiology, pathophysiology, risk factors and clinical features of varicella infection. It describes the current and possible future management strategies for preventing varicella infection and reactivation and for treating PHN...
October 13, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/29023181/review-for-disease-of-the-year-varicella-zoster-virus-induced-anterior-uveitis
#20
Ilknur Tugal-Tutkun, Luca Cimino, Yonca Aydin Akova
Varicella zoster virus (VZV)-induced anterior uveitis (AU) may complicate the course of primary varicella infection typically seen in children. In adults, especially with advanced age, VZV AU is more commonly associated with herpes zoster ophthalmicus (HZO) with or without skin rash affecting the distribution of the ophthalmic nerve due to reactivation of the latent VZV in the trigeminal ganglion. While it is typically a mild self-limiting AU in primary infection, HZO AU is often accompanied by keratitis, may have a chronic recurrent course, and lead to sectoral iris atrophy, pupillary distortion, and ocular hypertension...
October 12, 2017: Ocular Immunology and Inflammation
keyword
keyword
15696
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"